AR101 Real-World Open-Label Extension Study

Exclusion Criteria

• •Developed a clinically significant change in health status during the ARC007 study which in the opinion of the investigator would make the subject unsuitable for participation in this study.
• •Receiving a prohibited medication or anticipated use of a prohibited medication \[e.g., angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers or calcium channel blockers\], any monoclonal antibody, any investigational peanut immunotherapy, or any other immunomodulatory therapy.
• •Currently in the build-up phase of immunotherapy for any nonfood allergen.
• •Currently participating in any other interventional clinical study outside of the ARC007 study that was just completed.